Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: A prospective series from Spain

Hepatology

Volumn 44, Issue 4, 2006, Pages 850-856

  Lucena, M Isabel ^a,m   Andrade, Raúl J ^a   Fernández, M Carmen ^b   Pachkoria, Ketevan ^a   Pelaez, Gloria ^b   Durán, José A ^c   Villar, Macarena ^c   Rodrigo, Luis ^d   Romero Gomez, Manuel ^e   Planas, Ramón ^f   Barriocanal, Anabel ^f   Costa, Joan ^f   Guarner, Carlos ^g   Blanco, Sonia ^h   Navarro, José M ⁱ   Pons, Fernando ^j   Castiella, Agustin ^k   Avila, Susana ^l  

^a Grupo de Estudio para Las Hepatopatias Asociadas a Medicamentos   (Spain)

^b HOSPITAL TORRECÁRDENAS   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^e HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g HOSPITAL SANT PAU   (Spain)

^h HOSPITAL DE BASURTO   (Spain)

ⁱ HOSPITAL COSTA DEL SOL   (Spain)

^j HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^k Hospital Nuestra Senora de Aranzazu   (Spain)

^l Hospital de Lugo   (Spain)

^m Facultad de Medicina   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; DICLOFENAC; ERYTHROMYCIN; IBUPROFEN; KETOROLAC TROMETAMOL; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; CHOLESTATIC HEPATITIS; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; LIVER CELL DAMAGE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; TREATMENT DURATION; ADOLESCENT; AGE DISTRIBUTION; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG EFFECT; LIVER; LIVER DISEASE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROSPECTIVE STUDY; SPAIN; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; LIVER; LIVER DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SPAIN;

EID: 33750632721     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21324     Document Type: Article

References (28)

1. Cars O, Molstad S, Melander A. Variation in antibiotic use in the European Union. Lancet 2001;357:1851-1853.
2. Martinez-Mir I, Ferrer JM, Palop V, Estan L, Rubio E, Morales-Olivas FJ. Are the adverse drug reactions of amoxycillin and amoxycillin-clavulanic acid similar? Pharmacoepidemiol Drug Saf 1996;5:247-254.
3. van den Broek JW, Buennemeyer BL, Stricker BH. Cholestatic hepatitis caused by a combination of amoxicillin and clavulanic acid (Augmentin). Ned Tijdschr Geneeskd 1988;132:1495-1497.
4. Reddy KR, Brillant P, Schiff ER. Amoxicillin-clavulanate potassium-associated cholestasis. Gastroenterology 1989;96:1135-1141.
5. Larrey D, Vial T, Pauwels A, Castot A, Biour M, David M, et al. Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases. Gut 1992;33:368-371.
6. Hautekeete ML, Horsmans Y, Van Waeyenberge C, Demanet C, Henrion I, Verbist L, et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 1999;117:1181-1186.
7. O'Donohue J, Oien KA, Donaldson P, Underhill J, Clare M, MacSween RN, et al. Co-amoxiclav jaundice: Clinical and histological features and HLA class II association. Gut 2000;47:717-720.
8. Goossens H, Ferech M, Vander Stichele R, Elseviers M, ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: A cross-national database study. Lancet 2005;365:579-587.
9. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005;129:512-521.
10. Thomson JA, Fairley CK, Ugoni AM, Forbes AB, Purcell PM, Desmond PV, et al. Risk factors for the development of amoxycillin-clavulanic acid associated jaundice. Med J Aust 1995;162:638-640.
11. de Abajo FJ, Montero D, Madurga M, Garcia Rodriguez LA. Acute and clinically relevant drug-induced liver injury: A population based case-control study. Br J Clin Pharmacol 2004;58:71-80.
12. Garcia Rodriguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 1996;156:1327-1332.
13. O'Brien CS, Despott EJ, Hussaini SH, Dalton HR. A high incidence of drug-induced community jaundice in the UK: Flucloxacillin and co-amoxiclav are the main culprits [Abstract]. J Hepatol 2005;44(Suppl 4):P23.
14. Gresser U. Amoxicillin-clavulanic acid therapy may be associated with severe side effects - review of the literature. Eur J Med Res 2001;6:139-149.
15. Ryley NG, Fleming KA, Chapman RW. Focal destructive cholangiopathy associared with amoxycillin/clavulanic acid (Augmentin). J Hepatol 1995; 23:278-282.
16. Richardet JP, Mallat A, Zafrani ES, Blazquez M, Bognel JC, Campillo B. Prolonged cholestasis with ductopenia after administration of amoxicillin/ clavulanic acid. Dig Dis Sci 1999;44:1997-2000.
17. Andrade RJ, Lucena MI, Fernandez MC, Vega JL, Camargo R. Hepatotoxicity in patients with cirrhosis, an often unrecognized problem: Lessons from a fatal case related to amoxicillin/clavulanic acid. Dig Dis Sci 2001; 46:1416-1419.
18. Jordan T, Gonzalez M, Casado M, Suarez JF, Pulido F, Guerrero E, et al. Amoxicillin-clavulanic acid induced hepatotoxicity with progression to cirrhosis. Gastroenterol Hepatol 2002;25:240-243.
19. Benichou C. Report of an international consensus meeting. Criteria of drug-induced liver disorders. J Hepatol 1990;11:272-276.
20. Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez De La Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. HEPATOLOGY 2001;33:123-130.
21. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005;4:489-499.
22. Andrade RJ, Lucena MI, Alonso A, Garcia-Cortes M, Garcia-Ruiz E, Benitez R, et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. HEPATOLOGY 2004;39:1603-1612.
23. Lucena MI, Andrade RJ, Rodrigo L, Salmeron J, Alvarez A, Lopez-Garrido MJ, et al. Trovafloxacin-induced acute hepatitis. Clin Infect Dis 2000;30: 400-401.
24. Perez Moreno JM, Saldana Gonzalez FJ, Puertas Montenegro M, Baez Perea J. Cholestatic hepatitis caused by midecamycin. Gastroenterol Hepatol 1996;19:459-461.
25. Banks AT, Zimmerman HJ, Ishak KG, Harter JG. Diclofenac-associated hepatotoxicity: Analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. HEPATOLOGY 1995;22:820-827.
26. Horsmans Y, Geubel AP. Amoxycillin-calvulanic acid-erythromycin cross-liver toxicity: A case report. J Hepatol 1994;21:911-912.
27. Peire MA, Lucena MI, Ruiz-Extremera A, Jara P, Romero-Gonzalez J, Andrade RJ. Toxicidad hepatica por fármacos. Donde estamos y hacia donde caminamos. An Esp Pediatr 2002;56:434-442.
28. Australian Adverse Drug Reactions Advisory Committee. Drug-induced liver disease: Antibiotics of continuing concern. Australian Adverse Drug Reactions Bulletin 1996;15:1-4.